Omega 3 Max 700 mg EPA - 500mg DHA - 120 Softgels

Revisione. The beneficial properties of fish oil are well known and are related to its fatty acid composition rich in omega-3 polyunsaturated fatty acids. In the last years a variety of epidemiological and clinical studies have demonstrated the efficacy of fish oil supplementation in the rheumatic diseases, in particular in rheumatoid arthritis. The anti-inflammatory effects of fish oil are linked to the production of alternative eicosanoids, to the reduction of proinflammatory cytokines, to the inhibition of the activation of T lymphocytes and of catabolic enzymes. Fish oil supplementation could represent a valuable support to the traditional pharmacological treatment of rheumatoid arthritis.

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Pubblicazione 1999 — abstract non disponibile: non vengono dedotti risultati.

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio clinico. Hyperlipidaemia related to antiretroviral therapy is a major issue in the management of HIV infection. In HIV positive patients, interventions on their lifestyles and dietary habits are only partially effective and pharmacological support is often required. However, fibrates and statins, interacting with antiretroviral therapy, may cause toxicity. A number of clinical trials have shown the effectiveness of omega-3 fatty acids on the hyperlipidaemia of HIV patients. In this study, the effect of six-month daily administration of omega-3 fatty acids on triglycerides, total and LDL cholesterol, and CD4 cell count was evaluated in a group of 20 HIV positive patients. Triglyceride levels significantly decreased, whilst total, LDL cholesterol and CD4 cell count did not vary. Fish oil therapy was well tolerated by all patients. Omega-3 fatty acids may contribute to reduce cardiovascular risk in HIV positive patients.

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Revisione. The beneficial effects of omega-3 polyunsaturated fatty acids have been widely described in the literature in particular those on cardiovascular system. In the last decade there has been an increased interest in the role of these nutrients in the reduction of articular inflammation as well as in the improvement of clinical symptoms in subjects affected by rheumatic diseases, in particular rheumatoid arthritis (RA). Nutritional supplementation with omega-3 may represent an additional therapy to the traditional pharmacological treatment due to the anti-inflammatory properties which characterize this class of lipids: production of alternative eicosanoids, reduction of inflammatory cytokines, reduction of T-lymphocytes activation, reduction of catabolic enzymes activity. The encouraging results of dietetic therapy based on omega-3 in RA are leading researchers to test their effectiveness on patients with other rheumatic condition

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Revisione. Omega-3 polyunsaturated fatty acids have been effective in reducing cardiovascular mortality in the recent GISSI-Prevenzione study. In a post-hoc analysis of this study an important observation has been the reduction of sudden cardiac death. The hypothesis that a protection from sudden death occurs because of antiarrhythmic effects of omega-3 fatty acids is supported by studies on cellular and animal models. A few intervention studies before the GISSI-Prevenzione and several retrospective analyses of epidemiological studies, in which nutritional variables connected with the intake of omega-3 fatty acids had been recorded, also support such a hypothesis. This review critically summarizes this type of evidence and indicates current research directions for its further validation.

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Patients with ischemic heart disease are often affected by a mixed hyperlipoproteinemia, where a hypercholesterolemia of various severity is accompanied by slight or moderate hypertriglyceridemia (type IIb dyslipidemia). Current epidemiologic evidence suggests that hypertriglyceridemia has not to be disregarded, particularly in certain subgroups of patients. We evaluated the effect of the association of simvastatin 10 mg/day [an hydroxymethyl-glutaryl-CoA (HMG-CoA) reductase inhibitor] and omega-3 polyunsaturated fatty acids (n3-PUFA) in comparison with simvastatin 10 mg/day alone. The subjects undergoing the study were affected by coronary artery disease and showed hypercholesterolemia (LDL-cholesterol > 160 mg/dl) and moderate hypertriglyceridemia (serum triglycerides 200-400 mg/dl) after 2 months of moderate dietary therapy for hyperlipidemia (Step 1 of the National Cholesterol Education Program [NCEP]). Thirty-n

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Revisione. Fish oil is rich in the long chain omega-3 (omega-3) polyinsaturated fatty acids (PUFA), Pioneering studies of Dyerberg and Bang primarily originate interests in this way. The low incidence of acute myocardial infarction they verified within the Greenland Eskimos suggested that a high dietary omega-3 PUFA intake due to marine food might protect against coronary heart disease. They showed that the Eskimos had a beneficial lipid pattern and that their balance between pro-aggregatory thromboxanes and anti-aggregatory prostacyclins was shifted towards an anti-thrombotic state. The two major omega-3 fatty acids are decosapentaenoic acid (EPA C 20:5, omega 3), with five double bonds, and docosahexaenoic acid (DHA C 22:6, omega 3), with six double bonds. These fatty acids' significant effects include reduction of plasma triglycerides and lipoprotein levels as well as of platelets thrombogenicity in the microcirculation, which is due

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Background Recent meta-analyses of randomized controlled trials have raised concerns that treatment with omega-3 fatty acids may increase the risk of atrial fibrillation (AF). However, these meta-analyses included at most 8 trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 randomized controlled trials with AF incidence data, incorporating both published and unpublished data. Methods Eligible studies were randomized controlled trials investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months of treatment with EPA/DHA, participants ≥50 years of age, and, where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was the occurrence of new-onset AF. Our primary hypothesis was that risk for AF would simultaneously depend on both omega-3 dose (above or

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Background/objective Residual cardiovascular risk persists despite intensive statin therapy in patients with established atherosclerotic cardiovascular disease (CVD). Omega-3 fatty acids, particularly high-dose eicosapentaenoic acid (EPA), have been proposed as adjunctive therapy, yet trial results conflict, likely due to formulation differences. We conducted a formulation-focused meta-analysis to determine whether high-dose EPA-dominant supplementation reduces cardiovascular events and to quantify the impact of mixed EPA/docosahexaenoic acid (DHA) regimens on efficacy. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched MEDLINE, Embase, CENTRAL, and trial registries through May 2025 for randomized controlled trials, including placebo-controlled and open-label designs, of high-dose EPA-dominant omega-3 (≥ 1.8 g/day; ≥ 50% EPA) in adults with established

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. Omega-3 fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been extensively studied for potential cardioprotective effects, yet their impact on cardiovascular outcomes remains debated due to heterogeneity in formulation, dose, and patient subgroups. This meta-analysis evaluated the effects of EPA and DHA supplementation on major adverse cardiovascular events (MACE) and atrial fibrillation (AF), including postoperative AF (POAF), in patients with established CVD. A systematic search of Embase, PubMed/MEDLINE, Scopus, and Web of Science (January 2010-December 2021) identified randomized controlled trials (RCTs) of combined EPA + DHA supplementation in secondary prevention or perioperative settings. Data were synthesized using RevMan v5.3 with a random

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background Omega-3 fatty acids (ω-3 FAs), particularly EPA and DHA, are recognized for their health benefits. However, their circulating levels after supplementation may be modulated by several factors, including sex, carriage of the apolipoprotein E ε4 (APOE4) allele, and the chemical form of the supplement. Krill oil delivers ω-3 FAs primarily as phospholipids, whereas fish oil provides them as triglycerides. Objectives This study aimed to compare EPA and DHA concentrations after supplementation with krill oil and fish oil and assess whether sex and APOE4 genotype modify responses to supplementation. Methods This double-blind, randomized clinical trial included 72 healthy adults (53 females, 19 males) matched for age and BMI. Participants received 1.1 g/d ω-3 FAs through either krill oil (n = 36) or fish oil (n = 36) for 12 wk. Plasma FAs were measured at baseline and at weeks 1, 2, 4, and 12 by GC-flame ionizatio

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background Structured triglycerides (STGs), in which eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are esterified with medium-chain triglycerides (MCTs), have demonstrated greater bioavailability and potential benefits in improving endurance and reducing post-exercise strength loss compared with physical mixtures (PMs) of EPA and MCTs. However, it remains unclear whether STGs have superior effects on blood EPA levels and muscular endurance and fatigue. This study compared the effects of 8-week STG and PM intake on blood EPA levels, muscular endurance, and fatigue following resistance exercise. Methods Twenty-eight healthy young men were randomly assigned to an STG group (n = 15) or a PM group (n = 13) in a double-blind, parallel-group, active comparator trial. Participants consumed 4,560 mg/day of the test oil (600 mg EPA, 260 mg DHA) for 8 weeks. After the intervention, the participants performed four

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Most omega-3 supplements contain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in defined ratios, yet their pharmacokinetic and anti-inflammatory effects are not fully understood. This systematic review and meta-analysis evaluated how EPA:DHA dosing ratios, alongside EPA+DHA daily dose, influence blood fatty acid profiles and inflammatory markers across 96 clinical trials published before February 2025. Standardized mean differences with 95% confidence intervals were calculated. EPA+DHA supplementation significantly increased EPA:DHA blood ratios and blood EPA+DHA levels, with larger effects in healthy individuals. Supplementation also reduced arachidonic acid (AA) and key inflammatory markers, C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), particularly in participants with underlying health conditions. Ratios <1.0 produced the greatest cytokine reductions, whereas ratios

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background APOE ε4 carriers have increased Alzheimer's disease risk and altered omega-3 metabolism. No large-scale prevention trials have tested high-dose docosahexaenoic acid (DHA) supplementation specifically in non-demented APOE ε4 carriers with low baseline omega-3 intake for early intervention. Methods We conducted a phase IIa 24-month, randomised, double-blind, placebo-controlled trial (NCT03613844) at the University of Southern California between September 2018 and May 2024. Participants aged 55-80 years without dementia, low dietary DHA intake ( Findings Of 739 screened individuals, 365 participants were randomised (181 LP arm, 184 no-LP arm). Mean age was 66.4 years (SD 5.7), 210 (58%) were female, 142 (39%) were Hispanic, 173 (47%) were APOE ε4 carriers. DHA supplementation increased CSF DHA/AA ratio at 6 months vs placebo (0.17 [95% CI 0.15-0.18] vs -0.02 [95% CI -0.04 to -0.0004]; difference 0.19 [95% CI

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Background Recent meta-analyses of randomized controlled trials have raised concerns that treatment with omega-3 fatty acids may increase the risk of atrial fibrillation (AF). However, these meta-analyses included at most 8 trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 randomized controlled trials with AF incidence data, incorporating both published and unpublished data. Methods Eligible studies were randomized controlled trials investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months of treatment with EPA/DHA, participants ≥50 years of age, and, where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was the occurrence of new-onset AF. Our primary hypothesis was that risk for AF would simultaneously depend on both omega-3 dose (above or

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Maternal prenatal docosahexaenoic acid (DHA) intake is critical for fetal brain and retinal development; however, evidence regarding its effects on offspring neurodevelopment and growth remains inconsistent. This systematic review and meta-analysis evaluated the efficacy of prenatal DHA supplementation on offspring neurodevelopmental outcomes (attention, motor, intelligence, language, executive function, and short-term memory) and growth parameters (birth weight, head circumference, gestational age, and birth length) in the general population. We analyzed randomized controlled trials (RCTs) from 2001 to 2023 across PubMed, Embase, and the Cochrane Library. Of 917 records, 21 RCTs were included in the systematic review, of which 19 were eligible for meta-analysis. The meta-analysis showed that prenatal DHA supplementation had no significant benefits on any neurodevelopmental outcome. Subgroup analyses revealed no improvemen

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background Defective deep placentation contributes to major obstetric complications, including preterm birth, preeclampsia (PE), and severe fetal growth restriction (FGR). Docosahexaenoic acid (DHA) supplementation may improve placental function, but evidence from randomized trials remains inconsistent. Objective To evaluate whether early DHA supplementation modifies clinical phenotypes associated with impaired placentation. Methods In this multicenter, double-blind, placebo-controlled trial (NCT02336243), singleton pregnant women Results Of 844 women screened, 809 were randomized (404 DHA, 405 placebo). The trial did not reach the planned sample size, and the observed event rate was lower than expected. The primary outcome occurred in 3.47% of the DHA group and 2.96% of the placebo group (RR = 1.17; 95% CI 0.55-2.50; p = 0.685). No significant differences were observed for severe FGR (RR = 0.79; 95% CI 0.22-2.95) o

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Dysglycaemia and periodontal inflammation frequently co-occur during pregnancy, but the microbial mechanisms linking these conditions and their potential for intervention remain incompletely understood. Here, we establish prospective pregnancy cohorts including more than 2500 volunteers and longitudinally profile oral microbiome dynamics in 534 pregnant women. We show that gestational diabetes mellitus (GDM) is associated with a progressive shift from Streptococcus-dominated oral microbiota to Prevotella/Porphyromonas-enriched dysbiosis. In mouse and cellular models, this dysbiotic oral microbiota induces periodontal inflammation, systemic IL-17 and IL-1β responses, suppression of glucagon-like peptide-1 and insulin, and exacerbation of hyperglycemia. Conversely, oral microbiota remodeling through transplantation of Streptococcus-dominated bacteria attenuates periodontal inflammation, restores glucagon-like peptide-

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. Omega-3 fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been extensively studied for potential cardioprotective effects, yet their impact on cardiovascular outcomes remains debated due to heterogeneity in formulation, dose, and patient subgroups. This meta-analysis evaluated the effects of EPA and DHA supplementation on major adverse cardiovascular events (MACE) and atrial fibrillation (AF), including postoperative AF (POAF), in patients with established CVD. A systematic search of Embase, PubMed/MEDLINE, Scopus, and Web of Science (January 2010-December 2021) identified randomized controlled trials (RCTs) of combined EPA + DHA supplementation in secondary prevention or perioperative settings. Data were synthesized using RevMan v5.3 with a random

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Revisione. Esta hoja trata sobre la exposición a la vitamina E en el embarazo y durante la lactancia. Esta información se basa en la literatura publicada disponible. No debe usarse como un sustituto de la atención médica o los consejos de su proveedor de atención de salud.

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Pubblicazione 2020 — abstract non disponibile: non vengono dedotti risultati.

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. CONTEXT AND OBJECTIVE Oxaliplatin is one of the chemotherapy regimens most used for treating colorectal cancer. One of the main limitations to its use is induction of peripheral neuropathy. Previous studies have shown that vitamin E can reduce the incidence of peripheral neuropathy by 50%. This study aimed to assess the effectiveness of vitamin E for prevention of oxaliplatin-induced peripheral neuropathy. DESIGN AND SETTING Prospective, phase II, randomized pilot study developed at a university hospital in the Greater ABC region. METHODS Patients were randomized five days before starting oxaliplatin treatment, to receive either vitamin E or placebo until the end of the chemotherapy regimen. The outcome was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 3, and specific gradation scales for oxaliplatin-induced peripheral neuropathy. Patients with colorectal and gastric cancer who

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Aim The term iron deficiency is used to indicate a condition in which the content of iron (Fe) in the organism is low, even before the consequent reduction in erythropoiesis comes about. This clinical situation is very frequent in patients in fertile age. The therapy commonly used (Fe salts) is often poorly tolerated. The use of a food supplement containing nutrients useful for improving the bioavailability of Fe and that is well tolerated can represent a valid alternative to iron therapy. Methods The present study examines 49 fertile women with iron deficiency, of normal weight and not undergoing estroprogestin treatment. The patients underwent 3 assessments: basal, after 30 and after 60 days to determine their complete haemochrome, blood iron, blood ferritin, blood transferrin, iron binding capacity, folates, TSH, FT3, and FT4. Following the basal assessment, patients were randomly assigned to 1 of 2 treatment gro

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio clinico. Aim This open preliminary pilot study was aimed to evaluate the effect of a new pharmaceutical complex (silybin+vitamin E+phospholipids - RealSIL-IBI-Lorenzini Pharmaceutical, Italy) on some parameters of metabolic syndrome and of liver fibrosis in patients with non alcoholic fatty liver disease (NAFLD) with or without the contemporaneous presence of hepatitis C virus (HCV)-related chronic hepatitis. Methods Eighty five patients were consecutively enrolled in the study and divided in 2 groups; the first group was represented by 59 patients affected by NAFLD, negative for other known causes of chronic liver damage (M/F= 39/20; median age and range: 44 years, 22-76, group A); the second group was represented by 26 patients (M/F=19/7; median age and range 51 years, 20-75, group B) with HCV-related chronic hepatitis associated to NAFLD. Adverse events and drop-outs were absent in all group and compliance at the study was abs

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Revisione. The review on iron, iodine, zinc, selenium, copper, molybdenum, vitamin C, vitamin E, vitamin K, carotenoids and polyphenols recommendations for Venezuela comprise the definitions adopted worldwide known as Dietary Reference Intakes (DRIs) that include Recommended Dietary Allowance (RDA), Estimated Average Requirement (EAR), Adequate Intake (AI) and Tolerable Upper Intake Levels (UL). The RDA for iron: 11 mg/day for infants < 1 year of age, 7-10 mg/day for children, 8-11 mg/day for males, 8-18 mg/day for females and 27 mg/day during pregnancy. RDA for iodine: 110-130 microg/day for infants, 90-120 microg/ day for children and adolescents, 150 microg/day for adults, 220 microg/ day for pregnancy and 290 microg/day during lactation. RDA Zinc: 2-3 mg/day for infants, 3-5 mg/day for children, 8-11 mg/day for male adolescents and adults, 8-9 mg/day for female adolescents and adults, 12 mg/day during pregnancy and 13 mg/day for lac

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.